-+ 0.00%
-+ 0.00%
-+ 0.00%

NEW MODEL-BASED ANALYSIS FURTHER SUPPORTS THE POTENTIAL OF TECVAYLI® (TECLISTAMAB-CQYV) PLUS DARZALEX FASPRO® (DARATUMUMAB AND HYALURONIDASE-FIHJ) TO REDEFINE LONG-TERM SURVIVAL EXPECTATIONS IN EARLY LINE RELAPSED/REFRACTORY MULTIPLE MYELOMA

Reuters·09/23/2026 13:47:24

Please log in to view news